Dupixent Lymphoma Lawsuit in District of Columbia
Last Updated: August 7, 2026
The District of Columbia's three-year statute of limitations for both personal injury and product liability claims gives residents additional time to pursue pharmaceutical and medical device injury cases. As the nation's capital, D.C. is home to federal regulatory agencies including the FDA, and its courts are familiar with pharmaceutical regulatory issues. The District's concentrated urban population and extensive medical infrastructure mean many residents have been prescribed these medications through local health systems.
Dupixent (dupilumab) is an injected biologic prescribed mainly for severe eczema. Lawsuits allege that it can cause or accelerate cutaneous T-cell lymphoma, and separately that it can mask the early symptoms of one already present and delay the diagnosis. Federal cases are coordinated in MDL 3180 in the D.N.J. In District of Columbia, the personal injury statute of limitations is 3 years and the product liability deadline is 3 years. These are allegations under examination, not established findings. NuLegal reviews these claims at no cost and connects qualified claimants with trial counsel.
Dupixent Lymphoma Claims in District of Columbia
Dupixent is prescribed most often for moderate-to-severe atopic dermatitis. The claims in this litigation allege two separate things: that the medication may cause or accelerate a cutaneous T-cell lymphoma, and that it may suppress the skin symptoms of one a patient already has — so the rash looks like eczema responding to treatment, the biopsy is not ordered, and the lymphoma is identified later. Both are allegations under active litigation, not established findings.
For a District of Columbia resident, two things decide whether a claim is viable: the medical facts and the filing deadline. The medical side is whether Dupixent was prescribed and whether a lymphoma was diagnosed — in either order. The legal side is District of Columbia's statute of limitations, and specifically how this state treats the discovery rule, discussed below.
District of Columbia legal landscape: D.C. applies strict liability for defective products under Restatement (Second) of Torts Section 402A and follows a contributory negligence standard — one of the few jurisdictions where any plaintiff fault can completely bar recovery. These doctrines shape how a product liability claim about a prescription biologic is pleaded and what a claimant must prove, which is why the analysis differs meaningfully from state to state.
Residents in Washington and the surrounding areas would typically obtain the pathology report from the facility that performed the skin biopsy, and the prescription history from the pharmacy or the prescribing dermatologist. Those two documents are the ones a review eventually turns on.
District of Columbia Statute of Limitations
In District of Columbia, the personal injury statute of limitations is 3 years and the product liability deadline is 3 years. A Dupixent claim is generally pleaded as a product liability claim about a prescription medication, so both deadlines can be relevant depending on how the claim is framed.
District of Columbia recognizes the discovery rule. Under it, the clock may begin when you discovered — or reasonably should have discovered — that your lymphoma might be connected to Dupixent, rather than on the date you were diagnosed. That distinction carries more weight in this litigation than in almost any other, because the connection is one claimants characteristically learn late: early cutaneous T-cell lymphoma is routinely treated as eczema for years, the medication was prescribed by the doctor treating that eczema, and nobody in the room at the time suggested the two might be related. A District of Columbia claimant who learned of the possible connection recently may have a live claim even where the diagnosis is old.
Do not assume a deadline has passed without having it checked. How the personal injury and product liability statutes interact, whether the discovery rule applies to your facts, and whether any tolling doctrine is available are questions that turn on the specifics of your case.
Personal Injury SOL
3 years
Product Liability SOL
3 years
Discovery Rule
Yes
Where a District of Columbia Case Is Filed
A District of Columbia claim can be brought in the D.C. Superior Court at the state level, or in federal court. The federal districts covering District of Columbia are the United States District Court for the District of Columbia.
A case filed in or removed to federal court is transferred by the Judicial Panel on Multidistrict Litigation into MDL 3180, pending in the D.N.J. before Judge Zahid N. Quraishi. That transfer is for coordinated pretrial proceedings — discovery, expert practice, and eventually bellwether trials. It groups cases that share common questions of fact; it decides nothing about whether any of them has merit. Cases that do not resolve during that process can be remanded to the district they came from for trial.
Transfer to New Jersey does not require a District of Columbia claimant to travel there. Counsel handles the filings and proceedings.
State court
D.C. Superior Court
Federal districts
United States District Court for the District of Columbia
What a District of Columbia Review Looks At
A review turns on four facts. If you are unsure about any of them, say so — an unknown answer routes the file to a person rather than closing it.
You were treated with Dupixent
You were prescribed Dupixent or dupilumab, whether in District of Columbia or elsewhere. Your pharmacy record names it if you are not certain of the brand.
A lymphoma was diagnosed
You were diagnosed with a lymphoma. Many people are told a subtype name — mycosis fungoides or Sézary syndrome — rather than the word lymphoma.
The two dates, in either order
Roughly what year the medication started and roughly what year the diagnosis came. A diagnosis that came first goes to the delayed-diagnosis theory rather than ruling you out.
Within the filing deadline
The claim falls inside District of Columbia's window (3 years for personal injury, 3 years for product liability). The discovery rule may extend it, and in this litigation it frequently does — the connection is usually learned late.
District of Columbia Dupixent Lymphoma FAQ
What is the statute of limitations for a Dupixent lymphoma claim in District of Columbia?
District of Columbia applies a 3-year statute of limitations to personal injury claims and a 3-year one to product liability claims. District of Columbia recognizes the discovery rule, so the clock may run from when you learned — or reasonably should have learned — that your lymphoma might be connected to Dupixent, rather than from the diagnosis itself. That distinction matters more here than in most litigation: early cutaneous T-cell lymphoma is routinely treated as eczema for years, and almost nobody is told by their prescriber that the medication might be involved. Deadlines are strict and missing one can bar a claim permanently.
Where would a District of Columbia Dupixent case be filed?
A District of Columbia claimant's case would be filed either in the D.C. Superior Court at the state level or in federal court. The federal districts covering District of Columbia are the United States District Court for the District of Columbia. Federal Dupixent cases are transferred into MDL 3180 in the D.N.J. before Judge Zahid N. Quraishi for coordinated pretrial proceedings, and cases that do not resolve there can be remanded to their home district for trial.
I was diagnosed before I started Dupixent. Does that end a District of Columbia claim?
Not automatically. These lawsuits plead two theories, and the second is that Dupixent can mask the early skin symptoms of a cutaneous T-cell lymphoma a patient already has, so the biopsy is not ordered and the disease is identified later than it would otherwise have been. That theory is specifically about patients whose lymphoma predates the prescription. The screening asks for both years and routes the file to a person rather than closing it.
How does District of Columbia product liability law apply to a prescription biologic?
D.C. applies strict liability for defective products under Restatement (Second) of Torts Section 402A and follows a contributory negligence standard — one of the few jurisdictions where any plaintiff fault can completely bar recovery. A Dupixent claim is a product liability claim about a prescription medication, so these District of Columbia doctrines govern how the claim is framed and what a claimant has to prove.
What do I need before a District of Columbia case review?
Nothing formal. It helps to know roughly what year you started Dupixent and roughly what year you were diagnosed, and which dermatologist or oncologist has the biopsy report. If you do not have those details, the screening accepts "not sure" — an unknown answer sends the file to a person rather than closing it. The pathology report, usually held by the facility that did the biopsy in Washington or nearby, is the document that eventually settles the diagnosis.
Do I need to travel to New Jersey to bring a claim?
No. MDL 3180 is where federal Dupixent cases are coordinated for pretrial work, but claimants are not required to appear there. Counsel handles filings and proceedings. A District of Columbia resident's case would be filed by counsel and coordinated from wherever it is filed.
What does a District of Columbia case review cost?
Nothing. NuLegal's review is free and carries no obligation. NuLegal reviews the claim and, where it qualifies, connects the claimant with trial counsel handling this litigation. Attorneys in this litigation work on a contingency fee basis. Submitting the form does not create an attorney-client relationship.
Related Resources
District of Columbia Residents: Don't Wait
District of Columbia's filing deadline is 3 years for personal injury claims. A free, no-obligation review takes a few minutes and tells you whether your claim fits the current filings.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.